000169025 001__ 169025
000169025 005__ 20240229133636.0
000169025 0247_ $$2doi$$a10.1016/j.jchromb.2021.122781
000169025 0247_ $$2pmid$$apmid:34051651
000169025 0247_ $$2ISSN$$a0378-4347
000169025 0247_ $$2ISSN$$a1387-2273
000169025 0247_ $$2ISSN$$a1570-0232
000169025 0247_ $$2ISSN$$a1572-6495
000169025 0247_ $$2ISSN$$a1872-812X
000169025 0247_ $$2ISSN$$a1873-376X
000169025 0247_ $$2ISSN$$a1878-5603
000169025 0247_ $$2ISSN$$a1879-1794
000169025 0247_ $$2altmetric$$aaltmetric:106146571
000169025 037__ $$aDKFZ-2021-01193
000169025 041__ $$aEnglish
000169025 082__ $$a540
000169025 1001_ $$aSauter, Max$$b0
000169025 245__ $$aBioanalysis of selinexor in mouse plasma micro-samples utilizing UPLC-MS/MS.
000169025 260__ $$aNew York, NY [u.a.]$$bScience Direct$$c2021
000169025 3367_ $$2DRIVER$$aarticle
000169025 3367_ $$2DataCite$$aOutput Types/Journal article
000169025 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1622468903_26845
000169025 3367_ $$2BibTeX$$aARTICLE
000169025 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000169025 3367_ $$00$$2EndNote$$aJournal Article
000169025 520__ $$aSelinexor, a first-in-class inhibitor of the nuclear export protein Exportin-1 (XPO1), was recently approved for the treatment of multiple myeloma in combination with dexamethasone, and as monotherapy for diffuse large B-cell lymphoma. To enable investigations of selinexor in mice, we established and validated an ultrahigh-performance liquid chromatography - tandem mass spectrometry (UPLC-MS/MS) assay in the plasma concentration range of 1-1000 ng/mL using plasma microsamples of 5 µL. Protein depletion with acetonitrile was used for efficient isolation of selinexor which was followed by a dilution step, resulting in a scalable sample processing. Quantification was performed with positive electrospray ionization tandem mass spectrometry in the selected reaction monitoring mode. Due to the high sensitivity of the quantification and the scalable sample processing procedure, the assay can be used for different concentration ranges to either further decrease the achievable lower limit of quantification or to reduce the amount of plasma used. The assay showed interday and intraday accuracy of 89.0-109.0% with a corresponding precision ≤ 14.1%. Suitability for investigations of selinexor in small animal experiments was demonstrated by determination of plasma selinexor in mice after oral administration.
000169025 536__ $$0G:(DE-HGF)POF4-312$$a312 - Funktionelle und strukturelle Genomforschung (POF4-312)$$cPOF4-312$$fPOF IV$$x0
000169025 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo01.inet.dkfz-heidelberg.de
000169025 650_7 $$2Other$$aBioanalysis
000169025 650_7 $$2Other$$aPharmacokinetics
000169025 650_7 $$2Other$$aSelinexor
000169025 650_7 $$2Other$$aTandem Mass Spectrometry
000169025 650_7 $$2Other$$aUPLC
000169025 7001_ $$aFoerster, Kathrin I$$b1
000169025 7001_ $$0P:(DE-He78)2b12a7cfc604eb9816670e995f7af508$$aBenzel, Julia$$b2$$udkfz
000169025 7001_ $$0P:(DE-He78)f746aa965c4e1af518b016de3aaff5d9$$aPfister, Stefan$$b3$$udkfz
000169025 7001_ $$0P:(DE-He78)a7c1bbac024fa232d9c6b78443328d9d$$aPajtler, Kristian W$$b4$$udkfz
000169025 7001_ $$aHaefeli, Walter E$$b5
000169025 7001_ $$aBurhenne, Jürgen$$b6
000169025 773__ $$0PERI:(DE-600)1491259-4$$a10.1016/j.jchromb.2021.122781$$gVol. 1176, p. 122781 -$$p122781$$tJournal of chromatography / B$$v1176$$x1570-0232$$y2021
000169025 909CO $$ooai:inrepo02.dkfz.de:169025$$pVDB
000169025 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)2b12a7cfc604eb9816670e995f7af508$$aDeutsches Krebsforschungszentrum$$b2$$kDKFZ
000169025 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)f746aa965c4e1af518b016de3aaff5d9$$aDeutsches Krebsforschungszentrum$$b3$$kDKFZ
000169025 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)a7c1bbac024fa232d9c6b78443328d9d$$aDeutsches Krebsforschungszentrum$$b4$$kDKFZ
000169025 9130_ $$0G:(DE-HGF)POF3-312$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vFunctional and structural genomics$$x0
000169025 9131_ $$0G:(DE-HGF)POF4-312$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vFunktionelle und strukturelle Genomforschung$$x0
000169025 9141_ $$y2021
000169025 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz$$d2021-01-30$$wger
000169025 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2021-01-30
000169025 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2021-01-30
000169025 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2021-01-30
000169025 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences$$d2021-01-30
000169025 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2021-01-30
000169025 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2021-01-30
000169025 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2021-01-30
000169025 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2021-01-30
000169025 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2021-01-30
000169025 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2021-01-30
000169025 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2021-01-30
000169025 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bJ CHROMATOGR B : 2019$$d2021-01-30
000169025 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5$$d2021-01-30
000169025 9201_ $$0I:(DE-He78)B062-20160331$$kB062$$lB062 Pädiatrische Neuroonkologie$$x0
000169025 9201_ $$0I:(DE-He78)HD01-20160331$$kHD01$$lDKTK HD zentral$$x1
000169025 980__ $$ajournal
000169025 980__ $$aVDB
000169025 980__ $$aI:(DE-He78)B062-20160331
000169025 980__ $$aI:(DE-He78)HD01-20160331
000169025 980__ $$aUNRESTRICTED